Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Separation Science|May 24, 2018
Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumorsLucie Benesova, Barbora Belsanova, Filip Kramar, et al.
Electrophoresis|September 15, 2006
Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injectionsMarek Minarik, Lucie Benesova, Lucie Fantova, et al.
Anticancer Research|July 15, 2009
Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking statusMilos Pesek, Lucie Benesova, Barbora Belsanova, et al.
Anticancer Research|September 10, 2014
The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected]Ondrej Fiala, Milos Pesek, Jindrich Finek, et al.
Pathology Oncology Research : POR|October 27, 2018
Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic CancerLucie Benesova, Tereza Halkova, Bohus Bunganic, et al.
Anticancer Research|June 13, 2014
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinibOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Best Practice & Research. Clinical Gastroenterology|May 12, 2021
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) - A Helicobacter-opposite pointIlja Tacheci, Rudolf Repak, Miroslav Podhola, et al.
Anticancer Research|December 27, 2011
Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced diseaseMilos Pesek, Marta Kopeckova, Lucie Benesova, et al.
Anticancer Research|March 16, 2016
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line ChemotherapyMartin Svaton, Ondrej Fiala, Milos Pesek, et al.
Anticancer Research|May 16, 2009
Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancerCyril Salek, Petra Minarikova, Lucie Benesova, et al.
Pageof 5